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The first overview of systemic adjuvant treatment for early breast cancer by The Early Breast Cancer Triallists' Collaborative Group (EBCTCG) was published in 1990. It demonstrated. over a 5 year period, a significant improvement in mortality for women over the age of 50 when treated with tamoxifen and for women under the age of 50 when treated with chemotherapy.
The publication in 1992 of the second EBCTCG overview provides us with reliable data over 10 years of follow-up (Early Breast Cancer TInallists ' Collaborative Group, 1992a,b) . It has answered a number of important questions, provided some unexpected results and raised a series of new issues to be addressed by future research, particularly in terms of the potential benefits to be realised by combinations of systemic chemotherapy and hormonal therapies in women of all ages.
The 1992 overview has confirmed the efficacy of chemotherapy for women under the age of 50, and of tamoxifen for women over the age of 50. For women aged less than 50. the use of adjuvant combination chemotherapy reduces the annual odds of recurrence by 37% with a standard deviation of ± 5% (SD5) and the annual odds of death by 27% (SD6). For women over the age of 50, the use of adjuvant tamoxifen reduces the annual odds of recurrence by 30% (SD2) and the annual odds of death by 19% (SD3). Since the vast majority of women who develop recurrent breast cancer ultimately die from the disease, it is anticipated that. after sufficiently long periods of follow-up, the reduction seen in the annual odds of death will match that seen for recurrence. To convert these figures into numbers which are more easily understood. a reduction in the annual odds of death of about 30% equates to approximately 12 extra women alive at 10 years for every 100 women treated with stage II breast cancer, and approximately six extra women alive at 10 years for every 100 women treated with stage I breast cancer. Although these improvements do not appear large, they should be considered in the context of the millions of women treated worldwide each decade for operable breast cancer. Adjuvant treatment of just one million women could well prevent, or substantially delay, an additional 100 000 deaths.
The first overview (Early Breast Cancer Triallists' Collaborative Group, 1990) suggested a limited role for hor-monal manipulation in women aged less than 50 with breast cancer. Data from trials of adjuvant tamoxifen suggested a significant reduction in the annual odds of recurrence, but no significant reduction in mortality. Data with respect to ovarian ablation were incomplete.
The 1992 overview has unexpectedly shown that ovarian ablation used as adjuvant therapy in this group of women results in a 30% (SD9) reduction in the annual odds of recurrence and a 28% (SD9) reduction in the annual odds of death. The magnitude of this effect shows no sign of diminishing even after 15 years of follow-up.
More detailed analyses of the tamoxifen trials in women aged less than 50 in the 1992 overview have also provided some surprises with respect to duration of tamoxifen administration. The previous interpretation of these analyses was misleading. since patients treated with both tamoxifen and chemotherapy had a shorter duration of tamoxifen administration (mean 1.6 years) than those treated with tamoxifen alone (mean 2.6 years). Thus. comparisons of tamoxifen duration between trials were likely to have been confounded by the use of chemotherapy. In the 1992 overview. unconfounded analyses of tamoxifen duration in 2216 women treated for a mean of 2.6 years have shown a reduction in the annual odds of recurrence of 277% (SD7) and in the annual odds of death of 17% (SDIO) . not dissimilar to the results achieved for women over the age of 50. Indeed. further breakdown of these data reveal that. when women aged less than 50 are treated with tamoxifen for 2 years or more, the reduction in the annual odds of recurrence is 43% (SD 1), and in the annual odds of death is 27% (SD17) -very similar to those figures described earlier for chemotherapy in this age group. However, it should be noted that because of relatively small numbers in these analyses the confidence intervals are much wider than those in the chemotherapy analyses. implying a degree of statistical instability to the results.
The first overview also suggested a limited role for chemotherapy when given alone to women over the age of 50. for whom a significant reduction in the annual odds of recurrence was demonstrated, but this did not translate into a significant effect on mortality. The 1992 overview, however. clearly shows that chemotherapy does in fact have a sigificant effect in this age group. reducing the annual odds of recurrence by 22% (SD4). and the annual odds of death by 14% (SD5).
Thus, for women aged less than 50. there are three effective treatments. namely chemotherapy. ovarian ablation and tamoxifen. And for women over the age of 50 there are two effective treatments, namely tamoxifen and chemotherapy. What is not known with any accuracy at the present time is what happens when these treatments are combined and whether the benefits are additive. Data now available from the 1992 overview. shown in Table I . suggest that, for women aged less than 50. tamoxifen may be less effective when given in combination with chemotherapy. in that the additional reductions in the annual odds of recurrence and death from the addition of tamoxifen were only 7% (SD4) and 3% (SD5) respectively when compared with chemotherapy alone For pre-or perimenopausal women the clinician decides for each individual patient whether he or she would recommend therapy with either chemotherapy or ovarian suppression in addition to the standard therapy of tamoxifen alone. For premenopausal patients. if uncertainty exists concerning either of these treatments. the clinician is free to offer randomisation to that option. Thus. after discussion and consent. patients may be randomised between chemotherapy and no chemotherapy or between ovarian suppression and no ovarian suppression, or may enter into both randomisations.
For women over the age of 50. the data from the 1992 overview already suggest that tamoxifen and chemotherapy have a largely independent action and that their effect may well be additive (Table Id and e) . However, it is as yet uncertain whether the additional toxicity from such combined modality therapy will be worthwhile to individual patients. This is illustrated by the fact that most postmenopausal women with breast cancer in the UK are not currently offered chemotherapy. This question is addressed in the ABC trial through a randomisation between tamoxifen alone and tamoxifen plus chemotherapy.
While the ABC trial is designed to be simple and to keep paperwork to a minimum, it is recognised that the additional discussion required in order to obtain patients' consent to randomisation will significantly increase the workload of participating clinicians. In recognition of this, preliminary funding of £30 000 has been granted by the Medical Research Council to provide participants with a sum of money. on a per capita basis. which can be used to pay for staff to support the running of the trial within individual centres. Examination of the recruitment data shows that the tnral is now clearly viable, and by the end of 1994 855 patients had been recruited to the ABC tnral. 545 from the UK and 310 from overseas. As a result of successful recruitment a definitive grant is now being sought through the UKCCCR to support the further running of the trial over the next few years.
The success of the ABC trial depends not only on dedicated clinicians, but also on a steady supply of patients who are prepared to give consent to be randomised into the study. To this end the trial has been developed in consultation with organisations representing the interests of patients, including BACUP. Breast Cancer Care and the UK Breast Care Nursing Society. It will also be important to widen the public debate concerning participation of patients in clinical trials. Currently patients are often taken aback when approached concerning a clinical trial: ideally they, should expect to be offered entry into clinical trials. By heightening public awareness and broadening discussion of these items, the ABC trial can make a contribution to achieving this aim.
The advisory group on health technologies has already recognised the importance of well-designed randomised trials to the research and development strategy of the National Health Service.'A trial such as the ABC trial has, on the basis of previous research, identified a possible improvement in the treatment of a major health problem. and sets out to test this in a large number of patients. Issues such as quality of life will be incorporated into the trial, as an additional and voluntary module to be conducted in certain centres, as it is clearly important to be able to determine whether the additional toxicities resulting from combined modality treatments are worthwhile in terms of improved outcome for patients. Of particular concern are the long-term toxicities that may result from ovarian ablation in the younger premenopausal women, as well as the shorter term, but nevertheless potentially substantial. toxicities that may result from the addition of chemotherapy to tamoxifen in post-menopausal women.
The results of the ABC trial will ultimately be analysed with respect to their impact and cost, allowing calculation of statistics such as number of women-years of life saved, the added costs of treatment and cost savings of a cured patient.
A study of the size of the ABC trial will also facilitate the development of parallel studies to investigate aspects of the biology of breast cancer. Of particular interest is the further investigation and refinement of markers that may predict for chemotherapy or endocrine responsiveness. In premenopausal women there is already a suggestion from a trial that compared adjuvant combination chemotherapy with adjuvant ovarian ablation that the benefits of ovarian ablation were mainly seen in patients with hormone receptor-positive tumours and the benefits of chemotherapy mainly in patients with hormone receptor-negative tumours (Scottish Cancer Trials Breast Group and ICRF Breast Unit. Guys Hospital. London. 1994). Other trials have suggested that CMF-type adjuvant chemotherapy may be most effective in patients with tumours negative for the c-erbB-2 oncogene (Allred et al.. 1992; Gusterson et al.. 1992) . while a trial of dose intensity incorporating adjuvant anthracycine based chemotherapy has suggested that dose-intensive anthracycline chemotherapy has its main effect in patients with tumours positive for the c-erbB-2 oncogene (Muss et al., 1994) . However. all of these studies are relatively small or derived from subgroups of larger studies and require confirmation. Wellconducted biological studies run alongside a trial of the size of the ABC study will be able to contribute significantly to this research. Ultimately the goal must be to identify reliable markers that will allow specific treatments, or combinations of treatments. to be targeted to the individuals most likely to benefit from them. If this can be achieved it will also be possible to spare patients from receiving treatments they do not require. as well as to identify patients not well served by the current generation of adjuvant therapies who will become candidates for experimental therapies. A side-effect of this activity will be the generation of a sizeable well-documented tumour bank which will be available for testing the significance of new markers identified by ongoing fundamental molecular biological and genetic research.
Any clinician currently treating patients with operable breast cancer who is not already entering patients into clinical trials is urged to join the ABC trial. It is only through participation in such studies as this that we will be able further to define optimal treatments for individual patients.
For further information and in order to discover who is coordinating the ABC trial in your region contact Lindsay Johnson by telephone. 0181 643 8901 extension 4188, or fax, 0181 770 7876.
